vs
礼蓝动物保健（ELAN）与RXO, Inc.（RXO）财务数据对比。点击上方公司名可切换其他公司
RXO, Inc.的季度营收约是礼蓝动物保健的1.3倍（$1.5B vs $1.1B），RXO, Inc.净利率更高（-3.1% vs -24.1%，领先21.0%），礼蓝动物保健同比增速更快（12.2% vs -11.9%），礼蓝动物保健自由现金流更多（$46.0M vs $-9.0M），过去两年RXO, Inc.的营收复合增速更高（26.8% vs -2.6%）
礼蓝动物保健是一家美国动物保健制药企业，专注于生产宠物及家畜用药品与疫苗。该公司原为礼来公司旗下子公司，2019年完成分拆独立，目前是全球第三大动物保健企业。
RXO是总部位于美国的头部运输及物流解决方案供应商，核心业务覆盖货运经纪、大件商品最后一公里配送、运输管理服务与全链路供应链优化支持，主要服务北美制造业、零售业及电商领域的客户。
ELAN vs RXO — 直观对比
营收规模更大
RXO
是对方的1.3倍
$1.1B
营收增速更快
ELAN
高出24.0%
-11.9%
净利率更高
RXO
高出21.0%
-24.1%
自由现金流更多
ELAN
多$55.0M
$-9.0M
两年增速更快
RXO
近两年复合增速
-2.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.5B |
| 净利润 | $-276.0M | $-46.0M |
| 毛利率 | 51.5% | — |
| 营业利润率 | -22.6% | -2.9% |
| 净利率 | -24.1% | -3.1% |
| 营收同比 | 12.2% | -11.9% |
| 净利润同比 | -3350.0% | -84.0% |
| 每股收益（稀释后） | $-0.55 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ELANRXO
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $1.2B | $1.4B | ||
| Q4 24 | $1.0B | $1.7B | ||
| Q3 24 | $1.0B | $1.0B | ||
| Q2 24 | $1.2B | $930.0M | ||
| Q1 24 | $1.2B | $913.0M |
净利润ELANRXO
| Q4 25 | $-276.0M | $-46.0M | ||
| Q3 25 | $-34.0M | $-14.0M | ||
| Q2 25 | $11.0M | $-9.0M | ||
| Q1 25 | $67.0M | $-31.0M | ||
| Q4 24 | $-8.0M | $-25.0M | ||
| Q3 24 | $364.0M | $-243.0M | ||
| Q2 24 | $-50.0M | $-7.0M | ||
| Q1 24 | $32.0M | $-15.0M |
毛利率ELANRXO
| Q4 25 | 51.5% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 57.5% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 50.9% | — | ||
| Q3 24 | 52.2% | — | ||
| Q2 24 | 58.2% | — | ||
| Q1 24 | 57.3% | — |
营业利润率ELANRXO
| Q4 25 | -22.6% | -2.9% | ||
| Q3 25 | -4.4% | -0.5% | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 5.0% | -2.1% | ||
| Q4 24 | -5.0% | -1.4% | ||
| Q3 24 | 54.3% | -1.9% | ||
| Q2 24 | -2.7% | — | ||
| Q1 24 | 1.0% | -1.3% |
净利率ELANRXO
| Q4 25 | -24.1% | -3.1% | ||
| Q3 25 | -3.0% | -1.0% | ||
| Q2 25 | 0.9% | -0.6% | ||
| Q1 25 | 5.6% | -2.2% | ||
| Q4 24 | -0.8% | -1.5% | ||
| Q3 24 | 35.3% | -23.4% | ||
| Q2 24 | -4.2% | -0.8% | ||
| Q1 24 | 2.7% | -1.6% |
每股收益（稀释后）ELANRXO
| Q4 25 | $-0.55 | $-0.28 | ||
| Q3 25 | $-0.07 | $-0.08 | ||
| Q2 25 | $0.02 | $-0.05 | ||
| Q1 25 | $0.13 | $-0.18 | ||
| Q4 24 | $-0.01 | $-0.17 | ||
| Q3 24 | $0.73 | $-1.81 | ||
| Q2 24 | $-0.10 | $-0.06 | ||
| Q1 24 | $0.06 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $545.0M | $17.0M |
| 总债务越低越好 | $3.9B | $387.0M |
| 股东权益账面价值 | $6.5B | $1.5B |
| 总资产 | $13.4B | $3.3B |
| 负债/权益比越低杠杆越低 | 0.60× | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资ELANRXO
| Q4 25 | $545.0M | $17.0M | ||
| Q3 25 | $505.0M | $25.0M | ||
| Q2 25 | $539.0M | $18.0M | ||
| Q1 25 | $487.0M | $16.0M | ||
| Q4 24 | $468.0M | $35.0M | ||
| Q3 24 | $490.0M | $55.0M | ||
| Q2 24 | $416.0M | $7.0M | ||
| Q1 24 | $345.0M | $7.0M |
总债务ELANRXO
| Q4 25 | $3.9B | $387.0M | ||
| Q3 25 | $4.0B | $387.0M | ||
| Q2 25 | $4.1B | $387.0M | ||
| Q1 25 | $4.4B | $387.0M | ||
| Q4 24 | $4.3B | $351.0M | ||
| Q3 24 | $4.4B | $352.0M | ||
| Q2 24 | $5.7B | $370.0M | ||
| Q1 24 | $5.8B | $351.0M |
股东权益ELANRXO
| Q4 25 | $6.5B | $1.5B | ||
| Q3 25 | $6.7B | $1.6B | ||
| Q2 25 | $6.8B | $1.6B | ||
| Q1 25 | $6.4B | $1.6B | ||
| Q4 24 | $6.1B | $1.6B | ||
| Q3 24 | $6.5B | $1.7B | ||
| Q2 24 | $5.9B | $579.0M | ||
| Q1 24 | $6.1B | $582.0M |
总资产ELANRXO
| Q4 25 | $13.4B | $3.3B | ||
| Q3 25 | $13.6B | $3.2B | ||
| Q2 25 | $13.7B | $3.2B | ||
| Q1 25 | $12.9B | $3.3B | ||
| Q4 24 | $12.6B | $3.4B | ||
| Q3 24 | $13.3B | $3.4B | ||
| Q2 24 | $13.8B | $1.8B | ||
| Q1 24 | $14.0B | $1.8B |
负债/权益比ELANRXO
| Q4 25 | 0.60× | 0.25× | ||
| Q3 25 | 0.59× | 0.24× | ||
| Q2 25 | 0.61× | 0.24× | ||
| Q1 25 | 0.69× | 0.24× | ||
| Q4 24 | 0.70× | 0.22× | ||
| Q3 24 | 0.67× | 0.21× | ||
| Q2 24 | 0.96× | 0.64× | ||
| Q1 24 | 0.95× | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $108.0M | $7.0M |
| 自由现金流经营现金流 - 资本支出 | $46.0M | $-9.0M |
| 自由现金流率自由现金流/营收 | 4.0% | -0.6% |
| 资本支出强度资本支出/营收 | 5.4% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $284.0M | $-8.0M |
8季度趋势，按日历期对齐
经营现金流ELANRXO
| Q4 25 | $108.0M | $7.0M | ||
| Q3 25 | $219.0M | $23.0M | ||
| Q2 25 | $237.0M | $23.0M | ||
| Q1 25 | $-4.0M | $-2.0M | ||
| Q4 24 | $177.0M | $-7.0M | ||
| Q3 24 | $162.0M | $-7.0M | ||
| Q2 24 | $200.0M | $-5.0M | ||
| Q1 24 | $2.0M | $7.0M |
自由现金流ELANRXO
| Q4 25 | $46.0M | $-9.0M | ||
| Q3 25 | $127.0M | $9.0M | ||
| Q2 25 | $180.0M | $9.0M | ||
| Q1 25 | $-69.0M | $-17.0M | ||
| Q4 24 | $130.0M | $-19.0M | ||
| Q3 24 | $120.0M | $-18.0M | ||
| Q2 24 | $166.0M | $-16.0M | ||
| Q1 24 | $-22.0M | $-4.0M |
自由现金流率ELANRXO
| Q4 25 | 4.0% | -0.6% | ||
| Q3 25 | 11.2% | 0.6% | ||
| Q2 25 | 14.5% | 0.6% | ||
| Q1 25 | -5.8% | -1.2% | ||
| Q4 24 | 12.7% | -1.1% | ||
| Q3 24 | 11.7% | -1.7% | ||
| Q2 24 | 14.0% | -1.7% | ||
| Q1 24 | -1.8% | -0.4% |
资本支出强度ELANRXO
| Q4 25 | 5.4% | 1.1% | ||
| Q3 25 | 8.1% | 1.0% | ||
| Q2 25 | 4.6% | 1.0% | ||
| Q1 25 | 5.4% | 1.0% | ||
| Q4 24 | 4.6% | 0.7% | ||
| Q3 24 | 4.1% | 1.1% | ||
| Q2 24 | 2.9% | 1.2% | ||
| Q1 24 | 2.0% | 1.2% |
现金转化率ELANRXO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 21.55× | — | ||
| Q1 25 | -0.06× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.06× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
